These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33810354)

  • 1. Immune Contexture of MMR-Proficient Primary Colorectal Cancer and Matched Liver and Lung Metastases.
    Ahtiainen M; Elomaa H; Väyrynen JP; Wirta EV; Kuopio T; Helminen O; Seppälä TT; Kellokumpu I; Mecklin JP
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33810354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of PD-L1 expression and CD8 lymphocyte infiltration in metastatic colorectal cancer and their prognostic significance.
    Xin H; Zhou C; Wang G; Liu Y; Zhang J; Liu Y; Li B; Zhang J; Su M; Li Z; Wang G
    Heliyon; 2023 Feb; 9(2):e13048. PubMed ID: 36814622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD3
    Karjula T; Elomaa H; Niskakangas A; Mustonen O; Puro I; Kuopio T; Ahtiainen M; Mecklin JP; Seppälä TT; Wirta EV; Sihvo E; Väyrynen JP; Yannopoulos F; Helminen O
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of Immune Environment Analysis in Small Bowel Adenocarcinomas with Verified Mutational Landscape and Predisposing Conditions.
    Wirta EV; Szeto S; Hänninen U; Ahtiainen M; Böhm J; Mecklin JP; Aaltonen LA; Seppälä TT
    Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32718028
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study.
    Jary M; Liu WW; Yan D; Bai I; Muranyi A; Colle E; Brocheriou I; Turpin A; Radosevic-Robin N; Bourgoin P; Penault-Llorca F; Cohen R; Vernerey D; André T; Borg C; Shanmugam K; Svrcek M
    Mol Oncol; 2022 Jun; 16(11):2260-2273. PubMed ID: 34954864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.
    Droeser RA; Hirt C; Viehl CT; Frey DM; Nebiker C; Huber X; Zlobec I; Eppenberger-Castori S; Tzankov A; Rosso R; Zuber M; Muraro MG; Amicarella F; Cremonesi E; Heberer M; Iezzi G; Lugli A; Terracciano L; Sconocchia G; Oertli D; Spagnoli GC; Tornillo L
    Eur J Cancer; 2013 Jun; 49(9):2233-42. PubMed ID: 23478000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
    Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
    Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic myofibroblasts exert immunosuppressive effects independent of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic ductal adenocarcinoma.
    Beckinger S; Daunke T; Aldag L; Krüger S; Heckl S; Wesch D; Schäfer H; Röcken C; Rahn S; Sebens S
    Front Oncol; 2023; 13():1160824. PubMed ID: 37207152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immuno-Contexture and Immune Checkpoint Molecule Expression in Mismatch Repair Proficient Colorectal Carcinoma.
    Giacomelli M; Monti M; Pezzola DC; Lonardi S; Bugatti M; Missale F; Cioncada R; Melocchi L; Giustini V; Villanacci V; Baronchelli C; Manenti S; Imberti L; Giurisato E; Vermi W
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Artificial Intelligence Score and Immune Infiltrates as Prognostic Factors in Colorectal Cancer With Brain Metastases.
    Randrian V; Desette A; Emambux S; Derangere V; Roussille P; Frouin E; Godet J; Karayan-Tapon L; Ghiringhelli F; Tougeron D
    Front Immunol; 2021; 12():750407. PubMed ID: 34733283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
    Noh BJ; Kwak JY; Eom DW
    BMC Cancer; 2020 Jan; 20(1):58. PubMed ID: 31992245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors.
    Takamori S; Takada K; Tagawa T; Toyokawa G; Hirai F; Yamashita N; Okamoto T; Oki E; Yoshizumi T; Oda Y; Maehara Y
    Surg Oncol; 2018 Dec; 27(4):637-641. PubMed ID: 30449485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer.
    Liu S; Kong P; Wang X; Yang L; Jiang C; He W; Quan Q; Huang J; Xie Q; Xia X; Zhang B; Xia L
    Oncol Lett; 2019 Feb; 17(2):2335-2343. PubMed ID: 30675299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour-Infiltrating Lymphocytes (TILs) and PD-L1 Expression Correlate with Lymph Node Metastasis, High-Grade Transformation and Shorter Metastasis-Free Survival in Patients with Acinic Cell Carcinoma (AciCC) of the Salivary Glands.
    Hiss S; Eckstein M; Segschneider P; Mantsopoulos K; Iro H; Hartmann A; Agaimy A; Haller F; Mueller SK
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33669038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
    Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
    Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer.
    Zhou G; Noordam L; Sprengers D; Doukas M; Boor PPC; van Beek AA; Erkens R; Mancham S; Grünhagen D; Menon AG; Lange JF; Burger PJWA; Brandt A; Galjart B; Verhoef C; Kwekkeboom J; Bruno MJ
    Oncoimmunology; 2018; 7(7):e1448332. PubMed ID: 29900067
    [No Abstract]   [Full Text] [Related]  

  • 19. High immune cell infiltration predicts improved survival in cholangiocarcinoma.
    Wirta EV; Szeto S; Koppatz H; Nordin A; Mäkisalo H; Arola J; Sirén J; Ahtiainen M; Böhm J; Mecklin JP; Sallinen V; Seppälä TT
    Front Oncol; 2024; 14():1333926. PubMed ID: 38751812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis.
    Téglási V; Pipek O; Lózsa R; Berta K; Szüts D; Harkó T; Vadász P; Rojkó L; Döme B; Bagó AG; Tímár J; Moldvay J; Szállási Z; Reiniger L
    Clin Lung Cancer; 2019 Sep; 20(5):363-369.e2. PubMed ID: 31178388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.